• Mashup Score: 1
    2023 ASH AML Updates [Slides] - Kiran Naqvi MD - MOASC - 9 month(s) ago

    2023 ASH AML Updates [Slides] – Kiran Naqvi MD – MOASC Acute myeloid leukemia updates from our recent ASH from 2022 By Kiran Naqvi, MD Acute myeloid leukemia. These are the updates from our recent ASH from 2022 Acute myeloid leukemia. These are the updates from our recent ASH from 2022. So moving on. The first abs…

    Source: oncologytube.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of oncologytube
      oncologytube

      📊 AML updates by Kiran Naqvi MD at #MOASC23 @UCIrvineHealth @MOASC_Office: Oral arsenic, #sorafenib, CLIA-Venetoclax combo show promise in APL, core binding factor AML, FLT3-mutated AML. [Slides] [video]: https://t.co/C92i4Tz89l #AML #ASH2022 https://t.co/49q0InrAxY

  • Mashup Score: 0
    Pathogenic TP53 Mutations Associated With Poor Prognosis in Pediatric AML - 1 year(s) ago

    Dr. Adam Lamble of Seattle Children’s Hospital discusses findings that show pathogenic TP53 mutations are associated with a poor prognosis in children with acute myeloid leukemia (AML).

    Source: CheckRare
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CheckRare
      CheckRare

      Dr Adam Lamble at Seattle Children’s Hospital discusses a new study showing that pathogenic TP53 mutations, while rare, are associated with a poor prognosis in pediatric acute myeloid leukemia (AML). @seattlechildren @AML_Leukemia @AML_Hub #ASH2022 https://t.co/mJRkYJWm4Y

  • Mashup Score: 2
    Samhouri Discusses Practice Changing Data in the DLBCL Space - 1 year(s) ago

    In an interview with Targeted Oncology, Yazan Samhouri, MD, discussed new agents, clinical trials, and developments creating change in diffuse large B-cell lymphoma, as well as the key takeaways from ASH 2022.

    Source: Targeted Oncology
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of TargetedOnc
      TargetedOnc

      In an interview with Targeted Oncology, @yazansamhouri MD, discussed new agents, clinical trials, and developments creating change in diffuse large B-cell lymphoma, as well as the key takeaways from #ASH2022. #DLBCL #lymsm | @AHNtoday https://t.co/i3Rz2LOFb2

  • Mashup Score: 0
    Brentuximab: ASH 2022 Dr. Mitul Gandhi Updated Efficacy a... - 1 year(s) ago

    Brentuximab: ASH 2022 Dr. Mitul Gandhi Updated Efficacy and Safety Results By Mitul Gandhi, MD What were the results of the safety and efficacy of Brentuximab brand name ADCETRIS, in patients with Hodgkin Lymphoma? So this is a multi-center, multi-part study. Taking patients in this particular part B, evaluating pat…

    Source: oncologytube.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of oncologytube
      oncologytube

      Exciting developments in #oncology research #ASH2022! 💊👨‍⚕️🩺 Check out this insightful video discussing the potential benefits of precision medicine in cancer treatment. @VCSpecialists #ASH22 #HodgkinLymphoma Listen and Share the Audio Podcast Here: https://t.co/oOHx9TPhh8 https://t.co/kxlxfYwrQT

  • Mashup Score: 0
    Brentuximab: ASH 2022 Dr. Mitul Gandhi Updated Efficacy a... - 1 year(s) ago

    iFrame is not supported! Brentuximab: ASH 2022 Dr. Mitul Gandhi Updated Efficacy and Safety Results By Mitul Gandhi, MD What were the results of the safety and efficacy of Brentuximab brand name ADCETRIS, in patients with Hodgkin Lymphoma? So this is a multi-center, multi-part study. Taking patients in this particul…

    Source: oncologytube.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of oncologytube
      oncologytube

      Exciting developments in #oncology research #ASH2022! 💊👨‍⚕️🩺 Check out this insightful video discussing the potential benefits of precision medicine in cancer treatment. @VCSpecialists #ASH22 #HodgkinLymphoma Read and Share the Article Here: https://t.co/bHA5WwrnSr https://t.co/yphfbo9Zda

  • Mashup Score: 0
    Brentuximab: ASH 2022 Dr. Mitul Gandhi Updated Efficacy a... - 1 year(s) ago

    Brentuximab: ASH 2022 Dr. Mitul Gandhi Updated Efficacy and Safety Results By Mitul Gandhi, MD What were the results of the safety and efficacy of Brentuximab brand name ADCETRIS, in patients with Hodgkin Lymphoma? So this is a multi-center, multi-part study. Taking patients in this particular part B, evaluating pat…

    Source: oncologytube.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of oncologytube
      oncologytube

      Exciting developments in #oncology research #ASH2022! 💊👨‍⚕️🩺 Check out this insightful video discussing the potential benefits of precision medicine in cancer treatment. @VCSpecialists #ASH22 #HodgkinLymphoma Watch and Share the Video Here: https://t.co/I2vzTFx9M6 https://t.co/KK3Zo9sS33

  • Mashup Score: 0
    Odronextamab: ASH 2022 Won Seog Kim MD Prespecified Analy... - 1 year(s) ago

    Odronextamab: ASH 2022 Won Seog Kim MD Prespecified Analysis ELM-2 in DLBCL By Won Seog Kim, MD How can Odronextamab help patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)? I presented here the interim analysis data for the next one, monotherapy, in patients with relapsed refractory DLBCL…

    Source: oncologytube.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of oncologytube
      oncologytube

      Exciting news for the oncology community! Check out this prespecified analysis of the ELM-2 study on Odronextamab presented by Dr. Won-Seog Kim at #ASH2022. @skkuintl #ASH22 #DLBCL Listen and Share the Audio Podcast Here: https://t.co/3WkU9nJ6cf https://t.co/dxfX20nWfd

  • Mashup Score: 0
    Brentuximab: ASH 2022 Dr. Mitul Gandhi Updated Efficacy a... - 1 year(s) ago

    iFrame is not supported! Odronextamab: ASH 2022 Won Seog Kim MD Prespecified Analysis ELM-2 in DLBCL By Won Seog Kim, MD How can Odronextamab help patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)? I presented here the interim analysis data for the next one, monotherapy, in patients with …

    Source: oncologytube.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of oncologytube
      oncologytube

      Exciting news for the oncology community! Check out this prespecified analysis of the ELM-2 study on Odronextamab presented by Dr. Won-Seog Kim at #ASH2022. @skkuintl #ASH22 #DLBCL Read and Share the Article Here: https://t.co/qJVpdFwooM https://t.co/vN8LTXsEtz

  • Mashup Score: 0
    Odronextamab: ASH 2022 Won Seog Kim MD Prespecified Analy... - 1 year(s) ago

    Odronextamab: ASH 2022 Won Seog Kim MD Prespecified Analysis ELM-2 in DLBCL By Won Seog Kim, MD How can Odronextamab help patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)? I presented here the interim analysis data for the next one, monotherapy, in patients with relapsed refractory DLBCL…

    Source: oncologytube.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of oncologytube
      oncologytube

      Exciting news for the oncology community! Check out this prespecified analysis of the ELM-2 study on Odronextamab presented by Dr. Won-Seog Kim at #ASH2022. @skkuintl #ASH22 #DLBCL Watch and Share the Video Here: https://t.co/N0w6Vwbi15 https://t.co/QFor5SA83f

Load More